"Amyloid immunotherapy has consistently shown an increase in brain volume loss – leading to concerns in the media and medical ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

A study conducted bà Cattolica in Rome and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS has uncovered a ...

Scientists have created a game-changing 'Alzheimer's in a dish' model that allows for faster and more accurate testing of ...

An analysis of cerebrospinal fluid has uncovered several proteins likely involved in the development and progression of ...

(Reuters) -Cassava Sciences on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

Taking medications like blood pressure and lipid-lowering drugs for more than 5 years is associated with a lower incidence of ...